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The aim of this study was to assess the prevalence and the
common type of malignancies in Korean patients with poly-
myositis (PM) and dermatomyositis (DM) and to evaluate the
differences of clinical and laboratory findings between patients
with malignancy and those without malignancy. Forty-one
Korean patients, who were diagnosed as PM or DM, were
enrolled in this study. They fulfilled the Bohan and Peter's
criteria for a definite diagnosis of PM and DM. Patients with
PM were 25 and those with DM were 16. Eleven out of 41
patients (26.8%) had malignancies. The malignancy was
diagnosed simultaneously or later in 81.8% of patients with
inflammatory myopathy (IM). The breast cancer was the most
common malignancy. In this study, forty three years old as a
screening age for malignancy had 88.9% sensitivity and 50.2%
specificity. The serum levels of creatine kinase (CK) were
significantly lower in patients with malignancy than those
without malignancy.
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INTRODUCTION
It has been reported that the malignancy in the
inflammatory myopathy (IM) could be caused by
a part of the clinical course of IM itself, and
another part of paraneoplastic syndrome.1 How-
ever, the accurate mechanisms for their relations
have not been proved yet.2 A number of cases
have been reported since the report on gastric
cancer as the first malignancy related with poly-
myositis (PM) by Stertz in 1916.3 The previous
studies have reported that the prevalence of
malignancies in IM ranged from 4 to 42%, and
were exhibited more highly in the patients with
dermatomyositis (DM) than those with PM.4
However, few data have been reported in Asian
ethnic groups.5-7 Several cases of malignancies in
patients with IM were also reported in Korea,8,9
but they were insufficient to evaluate the pre-
valence or types of the malignancies in Korean
patients. Therefore, we sought to investigate the
prevalence and the common types of the
malignancies in the Korean patients who were
diagnosed as IM and to evaluate the differences
of clinical and laboratory findings between
patients with malignancy and those without
malignancy.
MATERIALS AND METHODS
The subjects of this study were 41 patients who
were diagnosed as PM or DM at Yonsei Uni-
versity Medical Center, Seoul, Korea from January
1995 to January 2003. All patients fulfilled the
Bohan and Peter's criteria for a definite diagnosis
of PM and DM.10 There were 25 patients with PM
and 16 patients with DM. The diagnosis of malig-
nancy with PM or DM was limited to the cases
that were definitely proved on the pathology.
All patients were retrospectively investigated
into age, sex, types of IM, clinical manifestations
and laboratory findings through the medical
records. The patients with malignancies were
analyzed into the primary organs of the malig-
nancy, the period between the diagnosis of IM
and that of malignancy, and the causes of death.
Malignancies in Korean Patients with Inflammatory
Myopathy
Sang-Won Lee, Sang Youn Jung, Min-Chan Park, Yong-Beom Park, and Soo-Kon Lee
Division of Rheumatology, Department of Internal Medicine, Institute for Immunology and Immunological Disease, BK21 Project
for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Received June 13, 2005
Accepted May 2, 2006
Reprint address: requests to Dr. Yong-Beom Park, Department
of Internal Medicine, Yonsei University College of Medicine, 134
Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-
2228-1967, Fax: 82-2-393-6884, E-mail: yongbpark@yumc.yonsei.
ac.kr
Sang-Won Lee, et al.
Yonsei Med J Vol. 47, No. 4, 2006
Laboratory findings included creatine kinase
(CK), lactate dehydrogenase, aspartate transami-
nase, alanine transaminase, erythrocyte sedimen-
tation rate (ERS, Westergren method), and C-
reactive protein (CRP). All laboratory data were
represented as levels at the time of diagnosis of
PM or DM.
Statistical analysis
All statistical analyses were conducted using
SPSS package for Windows (version 10.0). The
data were represented as mean ± SD, and the
comparison between the patients with malig-
nancy and those without malignancy was ex-
amined using Mann-Whitney U test and chi-
square test. The age requiring the screening test
for the malignancy in the patients with IM was
presumed using the receiver operation charac-
teristic curve.
RESULTS
Patient's characteristics
Of 41 patients diagnosed as IM, patients with
PM were 25 (9 men and 16 women) and those
with DM were 16 (4 men and 12 women). The
mean age at the diagnosis of IM was 43.7 ± 16.3
years (38.3 ± 16.0 for men and 46.1 ± 16.1 for
women) (Table 1).
Malignancy and inflammatory myopathy
Eleven of 41 patients were diagnosed as
malignancies (5 men and 6 women) including 6
patients with PM and 5 patients with DM. The
prevalence of malignancy in total patients with IM
was 26.8% (24% in patients with PM and 31.3%
in those with DM). The mean age at the diagnosis
of malignancy was 50.1 ± 12.6 years old (range, 31
to 76) (Table 1).
Table 1. Characteristics of 41 Patients with Polymyositis and Dermatomyositis
Polymyositis Dermatomyositis
TotalWith
malignancy
Without
malignancy
With
malignancy
Without
malignancy
Patients (n) 6 19 5 11 41
Men 3 6 2 2 13
Women 3 13 3 9 28
Age*
Male 9.0 ± 7.0 31.8 ± 12.2 63.5 ± 17.7 32.0 ± 29.7 38.3 ± 16.0
Female 53.3 ± 10.5 44.1 ± 13.9 47.7 ± 4.7 46.2 ± 23.0 46.1 ± 16.1
Laboratory findings
CK 2289.5 ± 2245.5 4235.0 ± 3.0 360.0 ± 222.8 1422.3 ± 2197.3 2723.2 ± 2998.4
ESR 27.2 ± 16.5 41.7 ± 33.2 20.4 ± 15.5 17.4 ± 10.8 30.5 ± 26.6
CRP 3.3 ± 6.0 1.2 ± 3.2 2.0 ± 2.1 0.2 ± 0.4 1.4 ± 3.3
LDH 631.7 ± 561.1 1031.9 ± 889.3 302.4 ± 260.0 772.9 ± 427.5 814.9 ± 713.0
AST 85.7 ± 81.6 150.4 ± 103.3 40.4 ± 16.1 80.1 ± 62.3 108.6 ± 91.4
ALT 71.0 ± 105.8 148.3 ± 121.6 17.6 ± 6.1 49.4 ± 22.6 94.5 ± 104.6
Incidence of malignancy 24.0% 31.3% 26.8%
Death (n) 3 1 4
CK, creatine kinase (IU/L); ESR, erythrocyte sedimentation rate (mm/hour); CRP, C-reactive protein (mg/dL); LDH, lactate dehydrogenase
(IU/L); AST, aspartate transaminase (IU/L); ALT, alanine transaminase (IU/L).
*Mean age at diagnosis of inflammatory myopathy (years).
CK in inflammatory myopathy with malignancy = 1412.5 ± 568.6 and CK in inflammatory myopathy without malignancy = 3203.8 ±
585.5, p < 0.05.
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The mean period from the diagnosis of IM to the
diagnosis of malignancy was 4.5 ± 16.3 months
(range, -12 to 51). Of these patients, 2 patients were
previously diagnosed as malignancy before the
diagnosis of IM, 6 patients were simultaneously
diagnosed as malignancy and IM, and 3 patients
were diagnosed as IM and then as malignancy.
The PM-patients group included each 1 case of
thyroid cancer, thymoma, hepatoma, pleural can-
cer, lung cancer and bladder cancer, and the DM-
patients group had 3 cases of breast cancer and
each 1 case of gastric cancer and nasopharynx
cancer. Women showed the breast cancer most
frequently as shown in 3 cases, and then each 1
case of lung cancer, bladder cancer, and pleural
cancer. Men exhibited each 1 case of gastric can-
cer, nasopharynx cancer, hepatoma, thyroid can-
cer, and thymoma (Table 2).
Four out of 11 IM patients with malignancies
were died, and the causes of death were due to
aspiration pneumonia, sepsis due to pneumonia,
sepsis of unknown etiology, and bony and hepatic
metastasis of primary tumor.
Clinical and laboratory findings between malig-
nancy and inflammatory myopathy
At the diagnosis of IM, the mean level of serum
CK was significantly lower as 1412.5 ± 568.6 IU/L
in the malignancy group than 3203.8 ± 585.5 IU/L
in the non-malignancy group (p < 0.05). The mean
levels of other enzymes originated from muscle in
the malignancy group were also lower than those
in the non-malignancy group, but there was no
statistical significance (p values of LDH, AST and
ALT were 0.12, 0.23, and 0.28, respectively).
Moreover, comparison between malignancy and
non-malignancy groups in each myositis type
showed no significant difference except CK level.
Assessment of age for screening of malignancy
When the cut-off value for screening of malig-
nancy in the patients with IM was set up as 43
years old, the sensitivity of the detection for
malignancy was 88.9% and the specificity was
50.2%. When the cut-off value was set up as 50 and
60 years old, the sensitivity was shown to be 55.6%
and 22.2% each and the specificity was 75.4% and
89.6%, respectively (area = 0.785, 95% confidence
interval = 0.599~0.971 and significance, p = 0.01).
DISCUSSION
The prevalence of malignancy in the patients
Table 2. Clinical and Laboratory Data of 11 Patients with Polymyositis and Dermatomyositis at Diagnosis of Malignancy
Case Sex* Age CK ESR CRP LDH AST ALT Myositis Organ Duration Survival Cause of death
1 M 44 3996 43 15 1141 87 45 PM Thyroid 0 S -
2 M 31 17 23 4.1 234 18 14 PM Thymus 11 S -
3 M 41 3950 13 0 243 74 23 PM Liver -4 S -
4 M 51 229 13 1 452 48 24 DM Nasopharynx 4 S -
5 M 76 478 42 3.5 151 40 12 DM Stomach 0 S -
6 F 46 35 14 0 125 16 12 DM Breast 0 S -
7 F 43 578 30 0.6 690 60 24 DM Breast -12 S -
8 F 53 480 3 5 94 38 16 DM Breast 0 D Bone and liver metastasis
9 F 43 4966 20 0.6 1521 244 285 PM Pleura 0 D Aspiration pneumonia
10 F 53 177 12 0 209 33 14 PM Lung 0 D Pneumonia
11 F 68 631 52 0.1 442 58 45 PM Bladder 51 D Sepsis
CK, creatine kinase (IU/L); ESR, erythrocyte sedimentation rate (mm/hour); CRP, C-reactive protein (mg/dL); LDH, lactate dehydrogenase
(IU/L); AST, aspartate transaminase (IU/L); ALT, alanine transaminase (IU/L); PM, polymyositis; DM, dermatomyositis; S, survival; D,
deceased.
*M, male; F, female.
Age at diagnosis of malignancy (years).
Duration from the diagnosis of myositis to that of malignancy (months).
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with IM has been diversely reported in the range
of 4 - 42%, and more frequently reported in the
patients with DM than in those with PM.4
According to the Cohort study conducted in
Sweden, Denmark and Finland by Hill et al., the
malignancies were found in 198 out of total 618
patients with DM as showing 32% of malignancy
prevalence.11 In this study, malignancies were
accompanied in 26.8% of the patients with IM, in
the concrete, in 24% of patients with PM and
31.3% of patients with DM. The patients with DM
generated higher prevalence of malignancies. This
result was similar to 32% shown in the study of
Hill et al.,11 but was higher than 15.3% of Mebazaa
et al. conducted in Tunisia.12 Wakata et al.
reported 18.8% of the prevalence of malignancies
in the Japanese patients with IM,5 and Chen et al.
found 18% of the prevalence of malignancy in 91
patients with DM in Taiwan,6 which showed
lower prevalence than that of our study.
According to Buchbinder et al., the malignancy
was simultaneously or later diagnosed in 74% of
the patients with IM, and was previously found
before the diagnosis of IM in 26% of them.2 Of the
patients in this study, the malignancy was simul-
taneously or later diagnosed in 81.8% of patients
with IM, and was diagnosed before diagnosis of
IM in 18.2% of them.
The mean age of patients with IM at the diag-
nosis of malignancy was 50.1 ± 12.6 years. This
was not significantly different from 49.6 years
reported by Mebazaa et al.,12 but was younger
than 62.1 years by Wakata et al.
5
Since the patients with IM have the tendency to
accompany malignancy, the screening test for
malignancy should be emphasized. However,
performing the screening test for all patients with
IM is inefficient and uneconomical, and therefore,
it is necessary to set up the age requiring the
screening test. According to our study with
Korean patients with IM, when the cut-off value
of age for the screening test of malignancy was set
up as 43 years, the sensitivity of the detection for
malignancy was 88.9% and the specificity was
50.2%. The screening test for the malignancy
might be necessary for the Korean patients with
IM aged over 43 years. In addition, the risk for
malignancy in patients with IM has been reported
to be highest within first year after diagnosis of
IM, decrease with time, and disappeared beyond
5 years.2,11 Our study showed the diagnosis of
malignancies in 8 of 11 patients with IM simulta-
neously or within first year as well. Thus,
screening work up for malignancy in patients over
43 years old should be performed as early as
possible after the diagnosis of IM.
The types of malignancies occurring in IM have
been variously reported according to locations
and races. Europe shows high prevalence of can-
cers in the ovary, lung, and gastrointestinal tract,
in patients with IM.11,13 According to Hill et al.,
the most frequent malignancy in patients with
DM was ovarian cancer, and the next frequent
malignancies were lung cancer, pancreas cancer,
non-Hodgkin's lymphoma, gastric cancer and
colon cancer in order.11 In addition, patients with
PM exhibited non-Hodgkin's lymphoma most fre-
quently, and then, lung cancer and bladder can-
cer. Chow et al. reported that the most frequent
malignancy was ovarian cancer in patients with
DM and malignancies in the lymph nodes or
hematopoietic organs in the patients with PM.13 In
contrast, Asia showed a high correlation between
nasopharynx cancer and DM. Chen et al. reported
that the most frequent malignancy related to DM
in Taiwan was nasopharynx cancer, and then the
next one was lung cancer.6 A study in Singapore
also reported that the nasopharynx cancer was the
most frequent malignancy.7 However, in the
present study with the Korean patients, breast
cancer was most frequently accompanying malig-
nancy. According to Korean Central Cancer Regis-
try program in 2000,
14
the frequent malignancies
in Korea were gastric cancer, hepatic cancer, lung
cancer, colon cancer, and bladder cancer in men,
and gastric cancer, breast cancer, cervix cancer,
colon cancer, and thyroid cancer in women in
order. Although, in this study, the frequency of
malignancy in IM was not corresponding to the
order of the frequency of malignancy in Koreans,
since the frequency and type of leading malig-
nancies has ethnic diversity, we suggest that the
protocol of screening work up should aim at those
developing frequently in each race. Indeed,
considering those leading malignancies in Korea,
we have performed chest CT, abdomen-pelvis CT,
upper and lower gastrointestinal endoscopies,
mammography, gynecologic evaluations, and
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neck ultrasonography for early detection of hid-
den malignancy in Korean patients with inflam-
matory myositis.
The clinical manifestations and laboratory
findings except CK between the patients with
malignancy and those without malignancy were
not significantly different in this study. The serum
levels of CK were significantly lower in the malig-
nancy group. Lakhanpal et al. have also reported
that the mean of the maximal levels of CK in
patients with polymyositis-dermatomyositis and
an associated malignant disease was lower than
those without cancer, however, its mechanism has
not been proven yet.15
In summary, the prevalence of malignancy in
Korean patients with IM was 26.8%. The breast
cancer was the most common malignancy. The
clinical manifestations and laboratory findings
were not significantly different except CK
between the patients with malignancy and those
without malignancy.
REFERENCES
1. Chakravarty E, Genovese MC. Rheumatic syndromes
associated with malignancy. Curr Opin Rheumatol
2003;15:35-43.
2. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G.
Incidence of malignant disease in biopsy-proven
inflammatory myopathy. A population-based cohort
study. Ann Intern Med 2001;134:1087-95.
3. Stertz G. Polymyositis. Berl Klin Wochenschr 1916;53:
489.
4. Mastaglia FL, Phillips BA. Idiopathic inflammatory
myopathies: epidemiology, classification, and diagnos-
tic criteria. Rheum Dis Clin North Am 2002;28:723-41.
5. Wakata N, Kurihara T, Saito E, Kinoshita M. Poly-
myositis and dermatomyositis associated with malig-
nancy: a 30-year retrospective study. Int J Dermatol
2002;41:729-34.
6. Chen YJ, Wu CY, Shen JL. Predicting factors of
malignancy in dermatomyositis and polymyositis: a
case-control study. Br J Dermatol 2001;144:825-31.
7. Chan HL. Dermatomyositis and cancer: East and West.
J Am Acad Dermatol 2000;42:699-700.
8. Choi SJ, Lee HY, Lee MH, Kim JH. A clinical analysis
of 39 patients with dermatomyositis-polymyositis.
Korean J Med 1985;21:104-11.
9. Kim SM, Choi YH, Oh MD, Nam TS, Chung MH, Pai
HJ, et al. A clinical analysis of 100 patients with
dermatomyositis-polymyositis. Korean J Med 1990;39:
812-22.
10. Bohan A, Peter JB. Polymyositis and dermatomyositis.
N Engl J Med 1975;292:403-7.
11. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E,
Mellemkjaer L, Airio A, et al. Frequency of specific
cancer types in dermatomyositis and polymyositis: a
population-based study. Lancet 2001;357:96-100.
12. Mebazaa A, Boussen H, Nouira R, Rokbani L, Ben
Osman-Dhahri A, Bouaouina N, et al. Dermatomyositis
and malignancy in Tunisia: a multicenter national
retrospective study of 20 cases. J Am Acad Dermatol
2003;48:530-4.
13. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK,
Olsen JH, Fraumeni JF Jr. Cancer risk following
polymyositis and dermatomyositis: a nationwide cohort
study in Denmark. Cancer Causes Control 1995;6:9-13.
14. Bae JM, Won YJ, Jung KW, Park JG. Annual report of
the Korea central cancer registry program 2000: based
on registered data from 131 hospitals. Cancer Res Treat
2002;34:77-83.
15. Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd.
Polymyositis-dermatomyositis and malignant lesions:
does an association exist? Mayo Clin Proc 1986;61:645-
53.
